Ophthalmology · Orlando, FL
NPI
1336303247
Since 2008
Specialty
Ophthalmology
Code 207W00000X
Group practices
1
Medicare group memberships
Hospitals
1
Hospital affiliations
95 Columbia St
Orlando, FL, 32806
Phone (407) 849-9621
Groups this clinician bills Medicare through
Medicare paid, 2024
$4.0M
41,859 services
Medicare patients, 2024
1,653
Average age 78
Drug cost, 2024
$374K
1,544 prescriptions
Company payments, 2025
$87K
From 14 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Matthew A Cunningham was code J2777 (injection, faricimab-svoa, 0.1 mg), 21,540 times for 83 patients. In total Matthew A Cunningham billed 41,859 services in 50 codes, and Medicare paid $4.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-04-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2777 Injection, faricimab-svoa, 0.1 mg | Office | 21,540 | 83 | $27.34 | $589K |
| J0177 Injection, aflibercept hd, 1 mg | Office | 2,720 | 115 | $261.41 | $711K |
| 67028 Intravitreal Injection | Office | 2,146 | 538 | $92.12 | $198K |
| Q5128 Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 1,855 | 77 | $180.92 | $336K |
| J2781 Injection, pegcetacoplan, intravitreal, 1 mg | Office | 1,800 | 23 | $116.29 | $209K |
| J0178 Injection, aflibercept, 1 mg | Office | 1,774 | 227 | $648.07 | $1.1M |
| 92134 Computerized Ophthalmic Imaging | Office | 1,660 | 696 | $29.85 | $50K |
| 92250 Angiography | Office | 1,579 | 1,390 | $25.82 | $41K |
| J3490 Unclassified drugs | Office | 1,116 | 76 | $207.30 | $231K |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 1,113 | 243 | $48.18 | $54K |
| J2782 Injection, avacincaptad pegol, 0.1 mg | Office | 1,040 | 12 | $86.58 | $90K |
| 92014 Ophthalmological E&M | Office | 854 | 790 | $81.09 | $69K |
| 99213 Office E&M - Established | Office | 736 | 574 | $64.82 | $48K |
| 99427 Chronic, Principal, and Transitional Care Management | Office | 387 | 194 | $36.52 | $14K |
| J2778 Injection, ranibizumab, 0.1 mg | Office | 345 | 21 | $124.38 | $43K |
By year: 2022 $3.7M for 20,524 services; 2023 $4.1M for 36,226 services; 2024 $4.0M for 41,859 services.
Medicare prescription drug claims, 2024
In 2024, the drug Matthew A Cunningham prescribed most often to Medicare patients was Prednisolone Acetate, with 331 prescriptions and refills. In total Matthew A Cunningham wrote 1,544 Medicare prescriptions that cost $374K.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisolone Acetate Generic | 331 | 530 | 178 | $13K |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 188 | 194 | 134 | $2,119 |
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 168 | 436 | 74 | $1,874 |
| Ketorolac Tromethamine Generic | 161 | 259 | 56 | $3,971 |
| Latanoprost Generic | 136 | 298 | 45 | $1,639 |
| Brimonidine Tartrate Generic | 108 | 194 | 39 | $1,865 |
| Eylea Aflibercept | 106 | 106 | 26 | $231K |
| Timolol Maleate Generic | 62 | 143 | 27 | $347 |
| Dorzolamide Hcl Generic | 32 | 76 | 12 | $552 |
| Atropine Sulfate Generic | 27 | 38 | 17 | $849 |
| Prednisone Generic | 24 | 24 | Under 11 | $135 |
| Syfovre Pegcetacoplan/Pf | 23 | 23 | Under 11 | $50K |
| Brimonidine Tartrate-Timolol Brimonidine Tartrate/Timolol | 23 | 37 | Under 11 | $1,572 |
| Combigan Brimonidine Tartrate/Timolol | 21 | 31 | Under 11 | $8,732 |
| Travoprost Generic | 18 | 27 | Under 11 | $3,371 |
Brand drugs: 656 claims; generic drugs: 888 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Matthew A Cunningham $87K ($79K in general payments such as food, travel and fees and $8,282 for research) from 14 companies. The largest payer was Genentech USA, Inc. with $19K.
| Company | Payments | Amount |
|---|---|---|
| Genentech USA, Inc. ROG.SW | 5 | $19K |
| Apellis Pharmaceuticals, Inc. APLS | 13 | $18K |
| Regeneron Healthcare Solutions, Inc. REGN | 13 | $18K |
| Astellas Pharma US Inc 4503.T | 13 | $14K |
| F. Hoffmann-La Roche AG ROG.SW | 4 | $8,282 |
| Alcon Vision LLC ALC | 8 | $3,157 |
| Ocular Therapeutix, Inc. OCUL | 3 | $2,438 |
| ANI Pharmaceuticals, Inc. ANIP | 9 | $2,274 |
| Alcon Research LLC ALC | 1 | $1,860 |
| Abbvie Inc. ABBV | 6 | $193 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.